| BSE: 532523 | Sector: Health care |
| NSE: BIOCON | ISIN Code: INE376G01013 |
| BSE 14:44 | 14 Aug | 582.50 |
10.65 (1.86%) |
OPEN
571.85 |
HIGH
585.30 |
LOW
570.30 |
| NSE 14:34 | 14 Aug | 583.00 |
11.30 (1.98%) |
OPEN
574.80 |
HIGH
586.00 |
LOW
570.10 |
| OPEN | 571.85 |
| PREVIOUS CLOSE | 571.85 |
| VOLUME | 81095 |
| 52-Week high | 695.00 |
| 52-Week low | 318.85 |
| P/E | 131.49 |
| Mkt Cap.(Rs cr) | 34,950 |
| Buy Price | 582.50 |
| Buy Qty | 1053.00 |
| Sell Price | 582.95 |
| Sell Qty | 102.00 |
9.00 pm | 31 Jul 2018 | Business Standard
The approval of Biocon's biosimilar insulin Glargin in about 25 countries will be a revenue driving force
11.28 am | 27 Jul 2018 | Business Standard
The stock rallied 10% to Rs 613 on the BSE after the company reported 48% growth in consolidated net profit at Rs 1.2 billion in June quarter.
9.28 pm | 23 Jun 2018 | Press Trust of India
Biocon said that it is committed to global standards of quality and compliance in a BSE filing after receiving the Establishment Inspection Report
2.20 am | 6 Jun 2018 | Business Standard
Analysts expect Biocon to gain 20-25 per cent market share and after factoring in a 20-25 per cent price erosion in the first year, they see its earni...
9.53 am | 5 Jun 2018 | Business Standard
The stock hit a record high of Rs 695, up 6% on the BSE in opening deal in otherwise weak market.
2.28 pm | 29 May 2018 | Business Standard
Biocon, Hexaware Technologies, Kotak Mahindra Bank and MM Forgings were among 13 stocks from the S&P BSE 500 and Smallcap index hitting new high on th...
9.38 am | 3 May 2018 | Business Standard
The stock dipped 4% to Rs 634 on the BSE in early morning trade.
1.23 am | 1 May 2018 | Business Standard
A month ago, Biocon announced that its biosimilar insulin glargine trademarked as Semglee received marketing approval from the European Commission
10.11 am | 20 Mar 2018 | Business Standard
We have at least a five-year head start in biosimilars compared with other Indian drugmakers, says Mazumdar-Shaw
2.28 am | 17 Feb 2018 | Business Standard
Regulatory tailwinds and launches in EU, US to drive earnings
